What is the name of your organization?
TIMSER
What is the name of your solution?
PREVENTIX
Provide a one-line summary or tagline for your solution.
cervical cancer screening test
In what city, town, or region is your solution team headquartered?
Mexico City, CDMX, Mexico
In what country is your solution team headquartered?
Mexico
What type of organization is your solution team?
For-profit, including B-Corp or similar models
Film your elevator pitch.
What specific problem are you solving?
Cervical cancer is the leading cause of death among women aged 24 to 35 in many low- and middle-income countries, despite being nearly 100% preventable with timely detection. The core issue is that current screening methods, such as Pap smears, are invasive, painful, and have low sensitivity. In many countries, Pap smears detect less than 50% of cervical cancers and fewer than 20% of precancerous lesions. Once cervical cancer is diagnosed, survival rates drop sharply—only about 50% of women survive. Globally, 90% of cervical cancer deaths occur in developing countries due to lack of access to effective screening. Over 70% of women are overdue for screening, putting millions at risk. Cultural, religious, and personal barriers often prevent women from undergoing traditional exams. Recognizing this crisis, the World Health Organization has declared cervical cancer a global health emergency and called for 70% of women to be screened with a highly sensitive, widely accessible test. Until now, such a test did not exist
What is your solution?
Preventix is the only blood-based test that screens for cervical cancer and precancerous lesions with high sensitivity. We have patented the use of specific biomarkers that are overexpressed at the earliest stages of cervical lesion development—before cancer even begins—enabling timely intervention and truly preventive care. This innovative test is currently available in Mexico as a Laboratory Developed Test (LDT). To expand accessibility, we are developing two diagnostic kit formats: an ELISA kit for use in clinical laboratories and a lateral flow test designed for point-of-care screening, particularly in geographically remote or underserved communities. Preventix is transforming cervical cancer prevention by offering a non-invasive, highly sensitive, and scalable solution that can reach the women most at risk. (for published articles go to www.preventix.global)
Who does your solution serve, and in what ways will the solution impact their lives?
Our solution is transforming how women access preventive care for cervical cancer, serving all sexually active women worldwide with a simple, accessible, and effective screening option.
